GENFIT welcomes a $20M milestone payment thanks to Iqirvo® performance

The biopharmaceutical company GENFIT will receive a $20 million milestone payment from Ipsen, following the achievement of $200 million in net sales of Iqirvo® in 2025. This achievement occurred in the first full year of marketing of the drug, indicating strong commercial performance.

Iqirvo®, used to treat primary biliary cholangitis (PBC), recorded $88 million in net sales in the fourth quarter of 2025, bringing its total to $208 million for the year. This strong performance confirms the strategic partnership between GENFIT and Ipsen.

Other developments include Ipsen's initiation of a Phase 3 clinical trial in primary sclerosing cholangitis (PSC), an indication with an unmet medical need, and the advancement of GENFIT's Phase 1b study for cholangiocarcinoma (CCA).